Immunocore’s primary therapeutic focus is oncology, and it also has well-advanced programs in infectious and autoimmune diseases. Immunocore has a pipeline of proprietary and partnered programmes in development and its lead program, IMCgp100, is in ongoing pivotal clinical studies as a treatment for patients with metastatic uveal (eye) melanoma.

Within oncology, Immunocore is applying its ImmTAC platform to overcome the limitations of current anti-cancer therapies to deliver:

• Potent and specific re-direction of a patient's own T cells to kill the target cancer cells.
• Access to a pool of antigenic targets that is up to nine-fold greater than traditional antibody-based therapies.

This unique and potent mechanism of action provided by ImmTAC molecules gives the potential to tackle diverse tumour types, including solid tumours that are characteristically immune excluded, or "cold" and thus resistant to the majority of existing immunotherapies that target activation of pre-existing immune cells. ImmTAC molecules have the potential to convert "cold" tumours to "hot" through their T cell redirectly activity.

Immunocore's transformation science and strong IP position has led to multi-target discovery partnerships with Genentech, GlaxoSmithKline, MedImmune (AstraZeneca) and Eli Lilly to devlelop new cancer therapies using the ImmTAC technology platform.

Outside of oncology, the Bill and Melinda Gates Foundation is supporting the expansion of Immunocore's technology platform to develop ImmTAV and ImmTAB molecules for the treatment of infectious diseases.